Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KIT

KIT

Basics

Aliases:
This biomarker is also known as:
  • proto-oncogene c-Kit,
  • soluble KIT variant 1,
  • proto-oncogene tyrosine-protein kinase Kit,
  • C-Kit,
  • Piebald trait protein,
  • p145 c-kit,
  • SCFR,
  • SCF-sR,
  • PBT,
  • v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog,
  • v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein,
  • CD117 antigen,
  • Piebald trait,
  • mast/stem cell growth factor receptor Kit,
  • CD117,
  • tyrosine-protein kinase Kit,

View in BioMuta

Description…

SCF-sR, also known as KIT, is the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. Human KIT is a tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KIT is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

KIT is known to be expressed in poorly differentiated breast cancer. (PMID:17867595). KIT is also thought to be a possible prognostic marker and possible molecular target for therapy in patients with BLBC. (PMID: 23319435)

Performance Comment

KIT was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Lung

Attributes

Phase: Two
QA State: Curated

Overview

KIT has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

SCF-sR, also known as KIT, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html